A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Public ClinicalTrials.gov record NCT02440685. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Study identification
- NCT ID
- NCT02440685
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Asana BioSciences
- Industry
- Enrollment
- 51 participants
Conditions and interventions
Conditions
- B-Cell Chronic Lymphocytic Leukemia
- B-Cell Leukemia, Chronic
- B-Lymphocytic Leukemia, Chronic
- Cancer
- Chronic Idiopathic Myelofibrosis
- Chronic Lymphocytic Leukemia
- Idiopathic Myelofibrosis
- Leukemia, Lymphocytic, Chronic
- Leukemia, Lymphocytic, Chronic, B Cell
- Lymphoma, B-cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Malignant
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T Cell, Peripheral
- Myelofibrosis
- Neoplasm
- Peripheral T-Cell Lymphoma
- T-Cell Lymphoma, Peripheral
- Tumor
Interventions
- ASN002 Dose Escalation Drug
- ASN002 RD Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2015
- Primary completion
- May 31, 2018
- Completion
- Jun 30, 2018
- Last update posted
- Jun 6, 2023
2015 – 2018
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology | Tempe | Arizona | 85284 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Winship Cancer Institute - Emory | Atlanta | Georgia | 30322 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| START - Midwest | Grand Rapids | Michigan | 49546 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02440685, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2023 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02440685 live on ClinicalTrials.gov.